CTD Subgroup

GRIPHON—The Largest PAH-CTD Subpopulation in a Randomized Controlled PAH Trial (n=334)1-3

The information below is from a post hoc subgroup analysis of the GRIPHON trial.
View the GRIPHON pivotal data for context of the overall population.

PAH-CTD baseline patient characteristics

PAH-CTD was a prespecified subgroup of the GRIPHON phase 3 trial (UPTRAVI: n=167, placebo: n=167)

Notable differences in baseline characteristics from overall population

The PAH-CTD subgroup had:

  • Shorter time from diagnosis (mean 1.7 years vs 2.4 years)
  • Older average age (52 years vs 48 years)
  • Larger percentage of female patients (90% vs 80%)

POST HOC ANALYSIS: 41% RISK REDUCTION OF DISEASE PROGRESSION IN PAH-CTD PATIENTS TREATED WITH UPTRAVI

Time to first disease progression event in patients with PAH-CTD

Events in patients with PAH-CTD

Adverse reactions in the PAH-CTD subgroup notably different from the overall population

  • Overall tolerability was generally consistent with overall population; however, 15 (9.1%) patients receiving placebo and 32 (19.2%) patients receiving UPTRAVI in the PAH-CTD subgroup discontinued treatment due to adverse reactions vs 41 (7.1%) and 82 (14.3%) in the overall population

GRIPHON—The Largest PAH-SSc Subpopulation in a Randomized Controlled PAH Trial (n=170)1-3

PAH-SSc baseline patient characteristics

Of the 334 patients with PAH-CTD in GRIPHON, 51% (n=170) had PAH-SSc.

Notable differences in PAH-SSc subtype vs overall population:

  • Mean age (UPTRAVI: 59 years vs 48 years; placebo: 61 years vs 48 years)
  • Asian population (5.9% vs 19.7%)
  • FC III population (64.7% vs 52.5%)
  • ERA + PDE-5i background therapy (36.5% vs 32.5%)

POST HOC ANALYSIS: 44% RISK REDUCTION OF DISEASE PROGRESSION IN PAH-SSc PATIENTS TREATED WITH UPTRAVI

Time to first disease progression event in patients with PAH-SSc

Events in patients with PAH-SSc

Adverse reactions in the PAH-SSc subpopulation notably different from the overall population§